Using a MTS cell proliferation assay, we found that RG7388 treatment leads to a robust decrease in cell proliferation in the three neuroblastoma p53 wild-type cell lines (IC50: 142 nM NGP, 247 nM SH-SY5Y, and 60 nM LAN-5; Figure 2a). This evidence concerns the gene TP53 and neuroblastoma.